Autel to Showcase Breakthrough EV Charging Innovations at ICNC23
Autel Energy, a leading provider of innovative EV charging solutions, is pleased to announce its participation in the highly-anticipated Intercharge Network Conference 2023 (ICNC23) to be held on August 29-31, 2023, in Berlin. Ting Cai, CEO of Autel Europe, is set to captivate the audience with an insightful speech on the future of EV charging. Autel's hallmark innovation, the MaxiCharger DC Compact, will take center stage as it makes a live demonstration at the Plug&Charge Showcase Zone to showcase its seamless charging process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828771064/en/
Complete MaxiCharger Lineup Unveiled at ICNC23 and IAA MOBILITY 2023 (Graphic: Business Wire)
ICNC23 is renowned for bringing together top industry professionals, experts, and stakeholders in the electric vehicle charging infrastructure domain. Ting Cai’s speech and Autel’s charging capabilities of its products will provide attendees with an exclusive opportunity to experience first-hand the cutting-edge technology that Autel Energy has brought to the market.
Autel MaxiCharger series offer a revolutionary charging solution that has transformed the charging experience for electric vehicle owners. With its high-speed charging capabilities, intuitive user interface, and compatibility with various electric vehicle models, Autel has earned its reputation as an indispensable tool for EV owners. Notably, Autel Energy has been officially checked and validated by Hubject, making its way into the Plug&Charge ecosystem. At ICNC23, Autel will bring its MaxiCharger DC Compact to demonstrate the charging process at the Plug&Charge Showcase Zone, which will impeccably showcase its exceptional features, emphasizing its role in providing a seamless and efficient charging process for electric vehicles.
Following the ICNC23, Autel Energy is excited to continue its engagement with the electric vehicle community at IAA MOBILITY 2023 (International Motor Show Germany) to take place on September 5-10, 2023, in Munich. During this period, Autel will embark on a roadshow, with its event vehicles journeying from ICNC in Berlin all the way to IAA MOBILITY in Munich and ultimately welcoming visitors at booth C2 A31.
"We are delighted to be part of ICNC23 and IAA MOBILITY 2023, where we can showcase the capabilities of Autel’s EV chargers and its seamless integration with various EV models," said Ting Cai, CEO of Autel Europe. "As the EV market continues to grow, Autel Energy remains committed to delivering cutting-edge charging solutions that enhance the driving experience for EV owners worldwide."
Visitors attending ICNC23 and IAA MOBILITY will have the exclusive opportunity to explore the charging process of the demonstration EV by Autel Energy's comprehensive array of EV charging products. Autel Energy's team of experts will be available at the event to engage with visitors, share insights, and discuss the transformative potential of their cutting-edge charging solutions.
For more information about Autel Energy and its EV charging solutions, please visit: https://autelenergy.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828771064/en/
Contact information
Jiaqi Liu
Email:jiaqi.liu@autel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom